

CHAMPIONS ONCOLOGY, INC.
Form 8-K
October 16, 2018

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): October 16, 2018

CHAMPIONS ONCOLOGY, INC.

(Exact name of registrant as specified in its charter)

| | | |
|---|--------------------------|--------------------------------------|
| Delaware | 001-11504 | 52-1401755 |
| (State or Other Jurisdiction of Incorporation) | (Commission File Number) | (IRS Employer Identification No.) |

1 University Plaza, Suite 307, Hackensack, New Jersey 07601
(Address of Principal Executive Offices) (Zip Code)

Registrant's telephone number, including area code: (201) 808-8400

Not applicable
(Former Name or Former Address if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the

Exchange Act. o

INFORMATION TO BE INCLUDED IN THE REPORT

Item 5.07. Submission of Matters to a Vote of Security Holders.

On October 16, 2018, Champion’s Oncology, Inc. (the “Company”) held its Annual Meeting of the Stockholders (the “Annual Meeting”). The following matters were submitted to a vote of the stockholders at the Annual Meeting and the voting results were as follows, there being no broker non-votes for any matter:

1. Election of Directors. The seven director nominees named in the Company's 2018 proxy statement were elected to serve for a one-year term expiring at the 2019 Annual Meeting of the Stockholders or until their successors are duly elected and qualified, based upon the following votes:

| Director Nominee | Votes For | Votes Withheld |
|----------------------|------------|----------------|
| Ronnie Morris, M.D. | 9,670,839 | 498,323 |
| Joel Ackerman | 9,639,721 | 529,441 |
| David Sidransky | 8,634,771 | 1,534,391 |
| Daniel Mendelson | 9,889,190 | 208,834 |
| Abba David Poliakoff | 9,960,328 | 208,834 |
| Scott R. Tobin | 10,025,199 | 143,963 |
| Philip Breitfeld | 9,588,601 | 580,561 |

2. Ratification of Appointment of Independent Registered Accounting Firm. The appointment of EisnerAmper LLP to serve as the Company’s independent registered public accounting firm for the fiscal year ending April 30, 2019, was ratified as follows:

| Votes For | Votes Against | Abstain |
|------------|---------------|---------|
| 10,168,385 | 769 | 8 |

3. Advisory Vote of the Compensation of the Company’s Named Executive Officers. The proposal to approve, on an advisory basis, the compensation of the Company's named executive officers, as described in the Company's 2018 proxy statement, was approved by the following votes:

| Votes For | Votes Against | Abstain |
|------------|---------------|---------|
| 10,119,809 | 40,553 | 8,800 |

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

CHAMPIONS
ONCOLOGY, INC.
(Registrant)

Date: October 16, 2018 By: /s/ David Miller
David Miller
Chief Financial Officer